Storys zum Thema Finanzen

Folgen
Keine Story zum Thema Finanzen mehr verpassen.
Filtern
  • 24.05.2023 – 10:53

    Incrementum AG

    In Gold We Trust Report 2023 "Showdown"

    Schaan / Vienna (ots) - On May 24, 2023, this year's - now 17th - In Gold We Trust report was presented at an international press conference broadcast live on the Internet. The authors of the report are the two fund managers Ronald-Peter Stöferle and Mark J. Valek from the Liechtenstein-based asset manager Incrementum AG. The 400+ page In Gold We Trust report is renowned worldwide and has been dubbed the "gold standard ...

  • 22.05.2023 – 11:53

    Germany Trade & Invest

    Germany Books Massive Foreign Direct Investment Increase in 2022

    Berlin (ots) - The United States and post-Brexit Britain drove an unprecedented level of FDI in Germany in the past year. Even without a huge investment by chipmaker Intel, the value of business expansion was up considerably. Despite the economic turmoil following Russia’s war on Ukraine, 2022 was a record year for international business expansion to Germany. That’s the conclusion of the annual FDI Report by Germany ...

  • 11.05.2023 – 11:01

    CROMA-PHARMA GmbH

    Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets

    Vienna (ots/PRNewswire) - Croma (Croma-Pharma® GmbH) announced today that it has received marketing authorisation for Letybo®, the company's botulinum toxin product, in 12 additional European markets. These include Belgium, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Luxembourg, Malta, Norway, Slovakia and Sweden. Letybo® will be launched in these ...

  • 09.05.2023 – 18:38

    CROMA-PHARMA GmbH

    /C O R R E C T I O N -- Croma-Pharma/

    Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows: Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter - ...